Literature DB >> 33291970

Minimal inhibitory concentration of seven antimicrobials to Mycoplasma gallisepticum and Mycoplasma synoviae isolates from six European countries.

Anno de Jong1, Myriam Youala1, Ulrich Klein1, Farid El Garch1, Shabbir Simjee1, Hilde Moyaert1, Markus Rose1, Anne V Gautier-Bouchardon2, Salvatore Catania3, Kannan Ganapathy4, Miklos Gyuranecz5, Franca Möller Palau-Ribes6, Andrew Pridmore7, Roger D Ayling8.   

Abstract

Mycoplasma gallisepticum and Mycoplasma synoviae are bacterial pathogens that cause disease in poultry, adversely affecting their health and welfare, and are a financial burden on producers. This manuscript describes the results of the MycoPath project that is the first international antimicrobial susceptibility programme for mycoplasma pathogens isolated from poultry. Improved comparative analysis of minimal inhibitory concentration (MIC) results from participating countries was facilitated by using one laboratory determining all MICs. Chicken and turkey isolates were obtained from France, Germany, Great Britain, Hungary, Italy and Spain during 2014-2016. One isolate per farm was retained. The MIC of seven antimicrobial agents was determined using a broth microdilution method, with Friis Medium (M. gallisepticum) or Modified Chanock's Medium (M. synoviae). Of the 222 isolates recovered, 82 were M. gallisepticum and 130 were M. synoviae. M. gallisepticum MIC50/90 values were 0.12/0.5, 2/8, 0.5/4, 0.12/>64, 0.008/0.062, 0.008/32, 0.062/4 mg/l for doxycycline, enrofloxacin, oxytetracycline, spiramycin, tiamulin, tilmicosin and tylosin, respectively. For M. synoviae, the values were 0.5/1, 8/16, 0.5/1, 0.5/8, 0.25/0.5, 0.062/2 and 0.062/16 mg/l respectively. A bimodal MIC distribution for the fluoroquinolone (enrofloxacin) and the macrolides (spiramycin, tilmicosin and tylosin) indicate that both species have sub-populations that are less susceptible in vitro to those antimicrobials. Some differences in susceptibilities were observed according to host species, Mycoplasma species, and country of origin. This study provides a baseline of novel data for future monitoring of antimicrobial resistance in poultry Mycoplasma species. Additionally, this information will facilitate the selection of the antimicrobial agents most likely to be effective, thus ensuring their minimal use with targeted and correct therapeutic treatments.Highlights First large-scale pan-European collection of representative Mg and Ms isolates.MIC values assessed in central laboratory for Mg and Ms from chickens and turkeys.Range of MIC values for 82 Mg and 130 Ms isolates to seven licenced antibiotics shown.Data can be used to help determine Mg and Ms veterinary-specific breakpoints.

Entities:  

Keywords:  Antimicrobial resistance; MIC; Mycoplasma gallisepticum; Mycoplasma synoviae; broth microdilution; chicken; turkey

Year:  2021        PMID: 33291970     DOI: 10.1080/03079457.2020.1861216

Source DB:  PubMed          Journal:  Avian Pathol        ISSN: 0307-9457            Impact factor:   3.378


  3 in total

1.  Antibiotic resistance of Mycoplasma Synoviae strains isolated in China from 2016 to 2019.

Authors:  Xiaorong Zhang; Mengjiao Guo; Di Xie; Yang Chen; Chengcheng Zhang; Yongzhong Cao; Yantao Wu
Journal:  BMC Vet Res       Date:  2022-01-03       Impact factor: 2.741

2.  The Monitoring of Mycoplasma gallisepticum Minimum Inhibitory Concentrations during the Last Decade (2010-2020) Seems to Reveal a Comeback of Susceptibility to Macrolides, Tiamulin, and Lincomycin.

Authors:  Marco Bottinelli; Michele Gastaldelli; Micaela Picchi; Arianna Dall'Ora; Lorena Cristovao Borges; Ana Sofía Ramírez; Andrea Matucci; Salvatore Catania
Journal:  Antibiotics (Basel)       Date:  2022-07-29

3.  Rational Use of Danofloxacin for Treatment of Mycoplasma gallisepticum in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift.

Authors:  Shuge Wang; Anxiong Huang; Yufeng Gu; Jun Li; Lingli Huang; Xu Wang; Yanfei Tao; Zhenli Liu; Congming Wu; Zonghui Yuan; Haihong Hao
Journal:  Antibiotics (Basel)       Date:  2022-03-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.